{
    "clinical_study": {
        "@rank": "168239", 
        "acronym": "TCAP", 
        "arm_group": [
            {
                "arm_group_label": "Ticagrelor", 
                "arm_group_type": "Experimental", 
                "description": "Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 180 mg loading dose followed by 90 mg BID for 90 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the drug ticagrelor will be an effective\n      treatment for patients with severe community acquired pneumonia. The primary objective is to\n      reduce all-cause mortality in the ticagrelor group compared to the placebo group."
        }, 
        "brief_title": "Ticagrelor in Severe Community Acquired Pneumonia", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Community Acquired Pneumonia", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1. Patients will have new \"severe\" CAP as defined by\n\n        a. New (within 72 hours of hospital admission) radiographic finding consistent with\n        pneumonia and admission or planned admission to an ICU for: i. Mechanical Ventilation\n        (invasive or non-invasive) OR ii. Vasopressors (dobutamine and phosphodiesterase are not\n        considered vasopressors for this criteria) OR iii. ICU admission due to severe respiratory\n        distress or arterial desaturation. b. At least two of the following; i. recent increase in\n        dyspnea ii. increased sputum production iii. change of character of sputum iv. White Blood\n        Cells > 12,000 or < 4,000 cells/mm3 or >10% bands v. Body temperature >38\u00baC or <36\u00baC (any\n        route)\n\n        Exclusion Criteria:\n\n          1. More than 72 hours have passed since meeting required inclusion criteria.\n\n          2. Development of pneumonia after 72 hours of current hospitalization.\n\n          3. Underlying disease likely to cause mortality within 90 days of randomization.\n\n          4. A resident in a hospital, not nursing home, within 30 days prior to development of\n             pneumonia.\n\n          5. Patients who are moribund (not expected to live for more than 48 hours).\n\n          6. No consent/inability to obtain consent from patient or surrogate.\n\n          7. Patient's physician is unwilling to have patient enter the study.\n\n          8. Age less than 50 years.\n\n          9. Pregnancy.\n\n         10. Breast feeding.\n\n         11. Underlying immunodeficiency (e.g. HIV, neutropenia, active hematologic malignancy,\n             functional or anatomical asplenia and hypogammaglobulinemia).\n\n         12. Patient, surrogate, or physician not committed to full support (exception: a patient\n             will not be excluded if he/she will receive all supportive care except for attempts\n             at resuscitation from cardiac arrest).\n\n         13. Unable to receive or unlikely to absorb enteral study drug (e.g., patients with\n             partial or complete mechanical bowel obstruction, intestinal ischemia, infarction,\n             and short bowel syndrome).\n\n         14. Hepatic impairment\n\n             a. Child Pugh score > 7 using data from outpatient setting\n\n         15. Conditions that increase the risk of bleeding, e.g.:\n\n               1. Surgery or the likely need for surgery during study, or evidence of active\n                  bleeding postoperatively (ICU procedures such as line placement, tracheostomy\n                  and chest tubes are not to be considered for this exclusion);\n\n               2. A history of severe head trauma requiring hospitalization or intra-cranial\n                  surgery within 3 months;\n\n               3. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or\n                  mass lesions of the central nervous system, hemorrhagic stroke or intracranial\n                  hemorrhage, or congenital bleeding diathesis;\n\n               4. Gastrointestinal bleeding within 6 weeks before the study unless a corrective\n                  procedure has been performed;\n\n               5. Recent trauma considered to increase the risk of bleeding.\n\n         16. Chronic renal disease requiring renal replacement therapy.\n\n         17. Creatinine > 3 mg/dL.\n\n         18. Platelet count < 50,000 /mm3.\n\n         19. Use of a P2Y12 inhibitor within the 3 months prior to randomization or physician\n             intent to initiate one of the CYP3A inhibitors, e.g.  ketoconazole, itraconazole,\n             voriconazole, clarithromycin, nefazodone, ritonavir, atazanovir, saquinavir,\n             nelfinavir, indinavir, or telithromycin.\n\n         20. Use of CYP3A inducers, e.g. rifampin, phenytoin, carbamazepine and phenobarbital.\n\n         21. Simvastatin or Lovastatin doses > 40 mg per day.\n\n         22. Digoxin use.\n\n         23. Receiving aspirin and physician and/or patient unwilling to reduce aspirin dose to\n             <100 mg per day.\n\n         24. Daily Non-steroidal anti-inflammatory drugs (NSAID) use as an outpatient (other than\n             Aspirin (ASA) as above).\n\n         25. Sick Sinus Syndrome, 2nd or 3rd degree heart block, bradycardia induced syncope  -\n             unless pacemaker in place.\n\n         26. Otherwise unsuitable for participation in the opinion of the investigator (i.e.,\n             homeless, non-compliant, etc.)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "568", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998399", 
            "org_study_id": "0001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ticagrelor", 
                "Placebo"
            ], 
            "intervention_name": "Placebo", 
            "intervention_type": "Other", 
            "other_name": "Placebo"
        }, 
        "intervention_browse": {
            "mesh_term": "Ticagrelor"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "CAP", 
            "Pneumonia", 
            "Intensive Care Unit", 
            "Mechanical Ventilation"
        ], 
        "lastchanged_date": "November 23, 2013", 
        "location": {
            "contact": {
                "email": "susan.mogan@vanderbilt.edu", 
                "last_name": "Susan Mogan, RN", 
                "phone": "615-343-2421"
            }, 
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37232"
                }, 
                "name": "Vanderbilt University Medical Center"
            }, 
            "investigator": {
                "last_name": "Todd Rice, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia", 
        "other_outcome": [
            {
                "description": "Only in patients on mechanical ventilation and assuming patient achieves 48 consecutive hours of unassisted breathing", 
                "measure": "Time to initiation of unassisted breathing", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Yes, No", 
                "measure": "Need for re-instituting assisted or mechanical ventilation after achieving 48 consecutive hours of unassisted breathing or comfort care chosen (withdrawal of support)", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Yes, No", 
                "measure": "Need for dialysis", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Includes ICU readmission if during same hospital stay", 
                "measure": "ICU length of stay", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "description": "In days", 
                "measure": "Hospital length of stay", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "description": "(Home, other facility, with or without assisted ventilation)", 
                "measure": "Discharge disposition", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }
        ], 
        "overall_contact": {
            "email": "gordon.bernard@vanderbilt.edu", 
            "last_name": "Gordon R Bernard, MD", 
            "phone": "615-343-0077"
        }, 
        "overall_contact_backup": {
            "email": "tonya.yarbrough@vanderbilt.edu", 
            "last_name": "Tonya R Yarbrough, RN", 
            "phone": "615-343-8155"
        }, 
        "overall_official": [
            {
                "affiliation": "Vanderbilt University", 
                "last_name": "Gordon R Bernard, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Virginia", 
                "last_name": "Jon D Truwit, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Alive or dead on day 90", 
            "measure": "All-cause mortality", 
            "safety_issue": "Yes", 
            "time_frame": "90 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998399"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Vanderbilt University", 
            "investigator_full_name": "Gordon Bernard", 
            "investigator_title": "Professor of Medicine, Associate Vice Chancellor for Research", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Not requiring pressor support for hypotension", 
                "measure": "Shock free days", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Ventilator free days", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Did the patient die during the hospitalization?", 
                "measure": "In-hospital mortality", 
                "safety_issue": "Yes", 
                "time_frame": "Throughout hospitalization"
            }, 
            {
                "description": "Number of days the patient is not in the hospital", 
                "measure": "Hospital free days", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }, 
            {
                "description": "Did the patient develop a stroke during the 90 day study?", 
                "measure": "Stroke", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Composite endpoint: stroke, myocardial infarct, mortality", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Did the patient have a myocardial infarction during the 90 day study?", 
                "measure": "Myocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }
        ], 
        "source": "Vanderbilt University", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Gordon Bernard", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}